Eli Lilly, known for its blockbuster weight-loss and anti-diabetes drugs, is now focusing on neurosciences, with significant ...
Despite beating quarterly sales and profit expectations, GSK's stock fell due to concerns over its drug pipeline and weak ...
Eli Lilly has announced that its experimental obesity drug, retatrutide, has outperformed Novo's Ozempic in a Phase 3 trial, ...
The Indian Patent Office has rejected a patent application for the BPaL regimen, a groundbreaking treatment for ...
Despite a $2.2 billion setback due to failed drug trials, Novartis raises its profit forecast for the year, highlighting ...
Despite a 30% cap on trade margins for non-scheduled cancer drugs, prices for branded cancer medications remain unchanged, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results